Compare · APLT vs FREQ
APLT vs FREQ
Side-by-side comparison of Applied Therapeutics Inc. (APLT) and Frequency Therapeutics Inc. (FREQ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both APLT and FREQ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- FREQ is the larger of the two at $175.1M, about 2.5x APLT ($70.8M).
- APLT has more recent analyst coverage (11 ratings vs 3 for FREQ).
- Company
- Applied Therapeutics Inc.
- Frequency Therapeutics Inc.
- Price
- $0.11+5.91%
- $15.00+5204.10%
- Market cap
- $70.8M
- $175.1M
- 1M return
- +3.66%
- -
- 1Y return
- -72.67%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2019
- News (4w)
- 0
- 0
- Recent ratings
- 11
- 3
Applied Therapeutics Inc.
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase I/II for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Frequency Therapeutics Inc.
Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on harnessing the body's innate biology to repair or reverse damage caused by a range of degenerative diseases. Its Progenitor Cell Activation approach, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. Frequency Therapeutics, Inc. has a licencse and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, Mass General Brigham, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.
Latest APLT
- SEC Form 15-12G filed by Applied Therapeutics Inc.
- SEC Form EFFECT filed by Applied Therapeutics Inc.
- SEC Form EFFECT filed by Applied Therapeutics Inc.
- Director Kanter Stacy J. returned 22,500 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Commercial Officer Hooks Corwin Dale was granted 312,500 shares and returned 862,500 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Officer Chinoporos Constantine was granted 437,500 shares and returned 1,000,000 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Skyler Jay S returned 22,500 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Financial Officer Funtleyder Leslie D. was granted 1,187,500 shares and returned 2,375,000 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Medical Officer Bailey Evan Prescott returned 1,235,915 shares to the company and was granted 437,500 shares, closing all direct ownership in the company (SEC Form 4)
- Director Lerner Teena returned 22,500 shares to the company, closing all direct ownership in the company (SEC Form 4)
Latest FREQ
- NorthStar Appoints Peter Pfreundschuh to Board of Managers
- SEC Form SC 13G/A filed by Frequency Therapeutics Inc. (Amendment)
- SEC Form SC 13G/A filed by Frequency Therapeutics Inc. (Amendment)
- SEC Form SC 13G filed by Frequency Therapeutics Inc.
- SEC Form SC 13G filed by Frequency Therapeutics Inc.
- SEC Form 424B3 filed by Frequency Therapeutics Inc.
- Frequency Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form EFFECT filed by Frequency Therapeutics Inc.
- SEC Form 424B3 filed by Frequency Therapeutics Inc.
- SEC Form S-1/A filed by Frequency Therapeutics Inc. (Amendment)